Structured JSON API for this factor page: https://sharemaestro.com/factors/api/tickers/c54d7c9b-29e6-4f69-80f6-14054a23e3ee/

ASND

Ascendis Pharma AS
Chart
261.00 USD
Latest Week 2026-07-17
HealthcareBiotechnologyLARGE
Snapshot 2026-07-19 · 0.6w · Fresh
0.11
OS Score
3.0%
Value
25.0%
Quality
83.0%
Momentum
5/9
F-Score
0.087
QV
StrategiesValueQualityMomentumCompositeInteractionsFactor AnalysisTrendsFundamentals
Strategy Eligibility
2 of 23 passing
★
OS Composite
✗
↗
Trending Value
✗
◆
Quality × Value
✗
🏛
Cornerstone Value
✗
🌿
Cornerstone Growth
✗
💎
Deep Value
✗
◇
VC2 Cheapest
✗
📐
EBITDA/EV
✗
◐
Veiled Value
✗
▣
Piotroski Bargains
✗
🔬
Quality Compounders
✗
📈
Consistent Earners
✗
🌱
GARP
✗
🔄
Shareholder Yield
✗
💰
High Yield
✗
🚀
Momentum Leaders
12-1 36%
◉
Market Leaders
✗
◎
Tiny Titans
✗
🔍
Small Cap Value
✗
🛡
Low Volatility
✗
🏷
Sector Cheapest
✗
🧠
Capital Allocators
CAQ 0.51
⚡
Risk-Adj Momentum
✗
V
Value Analysis
Cheapness relative to fundamentals
3.0%ile
P/E
33.8×
P/S
19.7×
P/B
35.0×
FCF Yield
0.004
EBITDA/EV
0.001
SH Yield
0.003
Relative Strength Across Value Dimensions
Multiples & Yields — Decomposition
VC1 (5-Factor)
99.00000000
/100 — 1=cheapest
VC2 (Trending Value)
99.00000000
/100
VC3 (Buyback)
99.00000000
/100
P/E of 33.8x is premium-priced — the market is paying up for expected growth. VC2 score of 99.00000000/100 — expensive across all six composite measures.
Q
Quality Analysis
Profitability, efficiency, balance sheet & earnings quality
25.0%ile
ROE
1.037
ROA
0.253
Net Margin
0.584
Op Margin
-0.006
GPA
0.381
D/E
3.11
Current
1.00
F-Score
5/9
Quality Radar — Relative Strength
Profitability & Leverage Breakdown
Rev Growth
1.353
Stability
12.222
lower=better
Accruals
0.224
lower=better
5yr Consist
No
ROE of 104% is exceptional. Highly leveraged with D/E of 3.11 — returns are being amplified by debt. Accruals ratio of 0.224 is elevated — earnings quality may be lower than headline numbers suggest.
M
Momentum & Risk
Price trend, volatility regime, risk-adjusted returns
83.0%ile
6M Return
26.8%
12M Return
53.6%
12-1 Mom
35.9%
Risk-Adj
0.97
Vol 252d
37.0%
Vol 60d
85.6%
↑ Expanding
Max DD 12M
-14.8%
Return Comparison — 6M / 12M / 12-1
Volatility Regime — 60d vs 252d
12-1 momentum of 36% is very strong — a clear uptrend. Near-term vol (86%) is expanding vs long-term (37%) — risk is increasing.
OS
Composite & Factor Heatmap
All factors at a glance
0.11
Pillar Balance — Value / Quality / Momentum
Factor Heatmap — green=strong, red=weak
▦
Sector Context
Healthcare · 500 peers
Sector Value %ile
2.2%
Sector Quality %ile
5.4%
P/E z-score
0.12
P/B z-score
1.39
Sector Avg OS
64.1%
Ticker vs Sector Averages
Relative Valuation Z-Score
Top Sector Peers (By OS)
SymbolNameOSValueQualityMomentum
FBIOP Fortress Biotech Inc Pref Series A 99.0% 98.0% 84.0% 96.0%
IRWD Ironwood Pharmaceuticals Inc 99.0% 92.0% 91.0% 98.0%
NUTX Nutex Health Inc 98.0% 91.0% 98.0% 80.0%
CGEN Compugen 98.0% 89.0% 96.0% 82.0%
TBPH Theravance Biopharma Inc 98.0% 90.0% 99.0% 84.0%
RIGL Rigel Pharmaceuticals Inc 98.0% 90.0% 93.0% 93.0%
FBIO Fortress Biotech Inc 98.0% 98.0% 84.0% 88.0%
MD Mednax Inc 97.0% 85.0% 84.0% 93.0%
Factor Interactions
Leveraged Returns
Strong ROE (104%) boosted by high leverage (D/E 3.1). Returns look good but come with balance sheet risk.
Earnings Quality Concern
ROE looks strong (104%) but high accruals (0.224) suggests earnings are accrual-heavy, not cash-backed.
Volatility Expanding
60-day vol (86%) significantly exceeds 252-day (37%). Near-term risk is elevated.
⚖
Factor Analysis
Comprehensive factor intelligence — strengths, weaknesses & cross-factor profile
Value
F
11.4% avg (6 factors)
Quality
C
53.9% avg (8 factors)
Momentum
B
73.6% avg (4 factors)
Risk
C
55.0% avg (1 factors)
▲ Top Strengths — highest scoring factors
▼ Key Weaknesses — lowest scoring factors
Score Trends7 snapshots
Factor Persistence7 snapshots
FactorCurrentStreakTrendSpark
OS Composite0.110—7—
Value %ile0.030—7—
Quality %ile0.250—7—
Momentum %ile0.830—5—
F-Score5.000—0—
Confidence0.881—7—
Volatility0.370—0—
Value Lens2021-07-20 → 2026-07-19
P/E Ratio
Earnings Yield
Value FactorsCheapness relative to fundamentals — lower multiples = cheaper
P/E Ratio
33.79
Price / Sales
19.73
Price / Book
35.05
Price / Cash Flow
297.05
FCF Yield
0.4%
EBITDA / EV
0.1%
Sales Yield (1/P·S)
0.0497
Shareholder Yield
Div + net buyback / mktcap
0.3%
Quality FactorsProfitability, efficiency, and balance sheet strength
Return on Equity
103.7%
Return on Assets
25.3%
Net Margin
58.4%
Operating Margin
-0.6%
Gross Profit / Assets
Novy-Marx GPA
38.1%
Debt / Equity
3.11
Current Ratio
1.00
Accruals Ratio
(NI-OCF)/Assets — lower=better
0.224
External Financing
Net issuance — lower=better
0.026
MomentumPrice trend strength over different horizons
6M Return
26.8%
12M Return
53.6%
12-1 Momentum
Jegadeesh-Titman (skip recent month)
35.9%
Risk-Adjusted Momentum
Mom 12-1 ÷ Vol
0.97
Growth & StabilityEarnings trajectory, consistency, and capital allocation
Revenue Growth (YoY)
135.3%
Earnings Stability (CV)
Lower = more stable
12.222
5yr Consistent
EPS up every year for 5 years
No
Piotroski F-Score
5
Buyback Yield
0.3%
O'Shaughnessy CompositesValue Composites (WWOWS 4th Ed) — 1=cheapest, 100=most expensive
VC1 (5-factor)
P/E+P/S+P/B+P/CF+EBITDA/EV
99
VC2 (6-factor)
VC1 + Shareholder Yield — used for Trending Value
99
VC3 (6-factor)
VC1 + Buyback Yield — no dividend preference
99
Capital Allocation & AlphaAlpha within factors — quality of management decisions
Veiled Value
Expensive by P/B, cheap by everything else
No
Market Leader
Above-avg mcap+revenue, non-utility
No
All Stocks Universe
Market cap > $200M
Yes
Tiny Titan
Micro-cap, low P/S, positive momentum
No
Quarterly Fundamentals
Revenue
Net Income
FCF
Net Margin
Show all
Op Income
OCF
CapEx
Equity
Annual Fundamentals
Revenue
Net Income
FCF
Net Margin
Show all
Op Income
OCF
CapEx
Equity